Format

Send to

Choose Destination
Lung. 2012 Jun;190(3):251-62. doi: 10.1007/s00408-011-9360-x. Epub 2012 Jan 25.

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Author information

1
Department of Pharmaceutical Sciences-Drug Development Division, College of Pharmacy, University of Kentucky, 789 S. Limestone Street, Lexington, KY 40536-0596, USA.

Abstract

Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.

PMID:
22274758
DOI:
10.1007/s00408-011-9360-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center